Not Yet RecruitingNot Applicable

The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

China50 participantsStarted 2025-03-01

Plain-language summary

The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age \> 18 years, regardless of gender.
✓. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
✓. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
✓. Availability of complete clinicopathological and follow-up data.
✓. Signed and dated informed consent form.

✕. Patients who have previously received anti-tumor therapy.
✕. Patients with a history of other malignancies.
✕. Incomplete clinical information or imaging data.
✕. Concurrent other malignant tumors.
✕. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
✕. Poor compliance.

Standardized uptake value (SUV)

Timeframe: Baseline and 7-10 days after treatment

NCT IDNCT06863441

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-12-31

Xinyu Zhang